Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties.

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...